Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin

Journal of Medicinal Chemistry

Volumn 42, Issue 25, 1999, Pages 5277-5283

  De Groot, Franciscus M H ^a   De Bart, Anton C W ^b   Verheijen, Jan H ^b   Scheeren, Hans W ^a  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; APROTININ; DAUNORUBICIN; DOXORUBICIN; PLASMIN; PRODRUG; UROKINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN MCF 7; DRUG CYTOTOXICITY; DRUG DEGRADATION; DRUG SYNTHESIS; ENZYME ACTIVATION; HUMAN; HUMAN CELL;

ANTIBIOTICS, ANTINEOPLASTIC; BIOTRANSFORMATION; DRUG SCREENING ASSAYS, ANTITUMOR; HALF-LIFE; HUMANS; HYDROLYSIS; MAGNETIC RESONANCE SPECTROSCOPY; PLASMIN; PRODRUGS; SPECTROMETRY, MASS, FAST ATOM BOMBARDMENT; TUMOR CELLS, CULTURED;

EID: 0033576644     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9910472     Document Type: Article

References (30)

1. Senter, P. D.; Svensson, H. P. A summary of monoclonal antibody-enzyme/prodrug. Adv. Drug Deliv. Rev. 1996, 22, 341-349.
2. A limitation of the use of monoclonal antibodies is their slow extravasation. In human studies, it was found that only 0.001% of the injected dose of antibody commonly localizes to each gram of tumor. Sands, H. Radioimmunoconjugates: an overview of problems and promises. Antibody Immunoconjugates Radiopharm. 1988, 1, 213-226.
3. Leenders, R. G. G.; Damen, F. W. P.; Bijsterveld, E. J. A.; Scheeren, H. W.; Houba, P. H. J.; van der Meulen-Muileman, I. H.; Boven E.; Haisma, H. J. Novel anthracycline-spacer-β-glucuronide, -β-glucoside and -β-galactoside prodrugs for application in selective chemotherapy. Bioorg. Med. Chem. Lett. 1999, in press.
4. Bosslet, K.; Straub, R.; Blumrich, M.; Czech, J.; Gerken, M.; Sperker, B.; Kroemer, H. K.; Gesson, J. P.; Koch, M.; Monneret, C. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res. 1998, 58, 1195-1201.
5. Bosslet, K.; Czech, J.; Hoffman, D. A novel one-step tumor selective prodrug activation system. Tumor Targeting 1995, 1, 45-50.
6. Houba, P. H. J.; Boven, E.; Erkelens, C. A. M.; Leenders, R. G. G.; Scheeren, J. W.; Pinedo, H. M.; Haisma, H. J. The efficacy of the anthracycline prodrug daunorubicin-GA3 in human ovarian cancer xenografts. Br. J. Cancer 1998, 78, 1600-1606.
7. Priebe, W. Anthracycline Antibiotics. New analogues, methods of delivery, and mechanisms of action; ACS Symposium Series 574; American Chemical Society: Washington, DC, 1995.
8. Yamashita, Y.-I.; Ogawa, M. Cell biologic factors and cancer spread (review). Int. J. Oncol. 1997, 10, 807-813.
9. Ruening, U.; Magdolen, V.; Wilhelm, O.; Fischer, K.; Lutz, V.; Graeff, H.; Schmitt, M. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis. Int. J. Oncol. 1998, 13, 893-906.
10. Andreasen, P. A.; Kjøller, L.; Christensen, L; Duffy, M. J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 1997, 72, 1-22.
11. Duffy, M. J. The biochemistry of metastasis. Adv. Clin. Chem. 1996, 32, 136-166.
12. Quax, P. H. A.; Van Muijen, G. N. P.; Weening-Verhoeff, E. J. D.; Lund, L. R.; Danø, K.; Ruiter, D. J.; Verheijen, J. H. Metastatic behaviour of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type I inhibitor, and urokinase-mediated matrix degradation. Cell Biol. 1991, 115, 191-199.
13. Quax, P. H. A.; de Bart, A. C. W.; Schalken, J. A.; Verheijen, J. H. The plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: correlation with metastatic behaviour in vivo. Prostate 1997, 32, 196-204.
14. Danø, K.; Behrendt, N.; Lund, L. R.; Ronne, E.; Pöllänen, J.; Solanen, E. M.; Stephens R. W.; Tapiovaara, H.; Vaheri, A. Cell surface plasminogen activation. In Cancer Metastasis; Schirrmacher, V., Schwartz-Albiez, R., Eds.; Springer-Verlag: Berlin, 1989; pp 98-107.
15. Hewitt, R.; Danø, K.; Stromal cell expression of components of matrix-degrading protease systems in human cancer. Enzyme Protein 1996, 49, 163-173.
16. Quax, P. H. A.; van Leeuwen, R. T. J.; Verspaget H. W.; Verheijen, J. H. Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines. Cancer Res. 1990, 50, 1488-1494.
17. Schmitt, M.; Harbeck, N.; Thomssen, C.; Wilhelm, O.; Magdolen, V.; Reuning, U.; Ulm, K.; Hofler, H.; Jänicke, F.; Graeff, H. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb. Haemost. 1997, 78, 285-296.
18. Emeis, J. J.; Verheijen, J. H.; Ronday, H. K.; de Maat, M. P. M.; Brakman, P. Progress in clinical fibrinolysis. Fibrinolysis Proteolysis 1997, 11, 67-84.
19. Ganesh, S.; Sier, C. F. M.; Heerding, M. M.; Vankrieken, J. H. J. M.; Griffioen, G.; Welvaart, K.; Vandevelde, C. J. H.; Verheijen, J. H.; Lamers, C. B. H. W.; Verspaget, H. W. Prognostic value of the plasminogen activation system in patients with gastric carcinoma. Cancer 1996, 77, 1035-1043.
20. Ganesh, S.; Sier, C. F. M.; Griffioen, G.; Vloedgraven, H. J. M.; de Boer, A.; Welvaart, K.; Vandevelde, C. J. H.; Verspaget, H. W. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res. 1994, 54, 4065-4071.
21. Chakravarty, P. K.; Carl, P. L.; Weber, M. J.; Katzenellenbogen, J. A. Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin. J. Med. Chem. 1983, 26, 638-644.
22. Carl, P. L.; Weber, M. J.; Katzenellenbogen, J. A. Hydrolytic enzyme-activatible pro-drugs. International Patent, 1981, WO 81/01145.
23. Lauck-Birkel, S.; Tang, W. C.; Wagner, B.; Fiebig, H. H.; Kohlmüller, D.; Eisenbrand, G. In Reduction of anticancer drug toxicity. Pharmacologic, biologic, immunologic and gene therapeutic approaches; Zeller, W. J., Eisenbrand, G., Hellmann, K., Eds.; Contrib. Oncol. 1995, 48, 189-194.
24. Eisenbrand, G.; Lauck-Birkel, S.; Tang, W. C. An approach towards more selective anticancer agents. Synthesis 1996, 1246-1258.
25. Dubowchik, G. M.; Radia S. Monomethoxytrityl (MMT) as a versatile amino protecting group for complex prodrugs of anticancer compounds sensitive to strong acids, bases and nucleophiles. Tetrahedron Lett. 1997, 38, 5257-5260.
26. Dubowchik, G. M.; Firestone, R. A. Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. Bioorg. Med. Chem. Lett. 1998, 8, 3341-3346.
27. Dubowchik, G. M.; Mosure, K.; Knipe, J. O.; Firestone, R. A. Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mytomycin c and doxorubicin. Bioorg. Med. Chem. Lett. 1998, 8, 3347-3352.
28. Carl, P. L.; Chakravarty, P. K.; Katzenellenbogen, J. A. A novel connector linkage applicable in prodrug design. J. Med. Chem. 1981, 24, 479-480.
29. Cell lines: MCF-7, breast cancer; EVSA-T, breast cancer; WIDR, colon cancer; IGROV, ovarian cancer; M19, melanoma; A498, renal cancer; H226, nonsmall cell lung cancer.
30. Kepers, Y. P.; Peters, G. J.; van Ark-Otte, J.; Winograd, B.; Pinedo, H. M.; Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur. J. Cancer 1991, 27, 897-900.